PrimeRFP SCOUT · Federal Contract Recompete Brief

75N93020C00016 — TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.

TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. is a federal NONE award for Department of Health and Human Services (HHS) held by VENATORX PHARMACEUTICALS, INC.. Estimated value $25M ($21.8M obligated). Current period of performance ends Jan 18, 2027. Last award drew 12 bidders.

$25M
Estimated Value
$21.8M
Obligated
Jan 18, 2027
PoP End / Expires
12
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

VENATORX PHARMACEUTICALS, INC. holds $44.4M across 6 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 12 offers. Set-aside status: NONE. Recompete timing centers on the Jan 18, 2027 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75N93020C00016
AgencyDepartment of Health and Human Services (HHS)
IncumbentVENATORX PHARMACEUTICALS, INC.
UEIMBBKNBU5DCC6
NAICS541715
PSCAN12
PoP end (current)Jan 18, 2027
Obligated$21.8M

TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.

Recompete timing

Public
Expiring in 155 days

Current PoP ends Jan 18, 2027 (155 days remaining). Agencies typically plan 12–18 months ahead — at 5.1 months out, that window is already open. The buying decision is likely already in motion.

Watch this contract — one email →

Incumbent footprint

Public record

VENATORX PHARMACEUTICALS, INC.$44.4M obligated across 6 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$44.8M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for 75N93020C00016
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open VENATORX PHARMACEUTICALS, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75N93020C00016?

75N93020C00016 (TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.) is a Department of Health and Human Services (HHS) award with an estimated value of $25M, currently held by VENATORX PHARMACEUTICALS, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75N93020C00016?

VENATORX PHARMACEUTICALS, INC. is the incumbent with $44.4M across 6 related awards in SCOUT’s public footprint. The current period of performance ends Jan 18, 2027.

When does 75N93020C00016 come up for recompete?

SCOUT tracks a period-of-performance end of Jan 18, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75N93020C00016